The therapeutic effects of ß-D-Mannuronic acid in patients with ankylosing spondylitis
Phase 1
- Conditions
- Ankylosing spondylitis.Ankylosing spondylitis
- Registration Number
- IRCT2013062213739N1
- Lead Sponsor
- Vice-Chancellor for Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Inclusion Criteria:
Patients age 18-45 years old, Diagnosis of Definite AS as defined by the modified New York criteria, Disease activity equal to BASDAI score = 4, Functional activity equal to BASFI score = 4, Each patient must sign written informed consent.
Exclusion Criteria
History of fever and Infectious diseases, Positive pregnancy test or Lactation, Other collagen- vascular diseases, Other auto-immune diseases, Malignancies, Patients have enrolled another clinical trial study within last 4 weeks, Other concomitant diseases (Hepatic, renal, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The ASAS20 response criteria. Timepoint: 12 weeks after intervention (at the end of study). Method of measurement: Questionnaire.;Disease activity. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Questionnaire.;Physical function. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Questionnaire.
- Secondary Outcome Measures
Name Time Method